Inhaled nitric oxide: current and future uses in neonates

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology
• Pharmacology

Background:

• Persistent pulmonary hypertension of the newborn (PPHN) is a critical condition in term and near-term neonates.
• Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator used for PPHN treatment.
• iNO improves pulmonary vascular resistance and ventilation/perfusion matching.

Purpose of the Study:

• To review the efficacy and application of inhaled nitric oxide in neonatal respiratory conditions.
• To outline optimal dosing, duration, and weaning strategies for iNO therapy.
• To discuss the role of iNO in conjunction with ventilatory support and during transport.

Main Methods:

• Review of clinical trials and existing data on iNO use in neonates.
• Analysis of iNO's physiological effects on pulmonary vasculature and gas exchange.
• Examination of treatment protocols, including dosing, weaning, and adjunctive therapies like HFOV.

Main Results:

• iNO reduces pulmonary vascular resistance, decreases extrapulmonary shunting, and improves ventilation/perfusion matching.
• Clinical trials show iNO diminishes the need for extracorporeal membrane oxygenation (ECMO).
• Optimal starting dose is 20 ppm; doses above 40 ppm offer no additional benefit. Therapy duration is typically under one week.

Conclusions:

• iNO is an effective treatment for PPHN in term and near-term neonates, reducing the need for ECMO.
• Careful weaning from iNO is essential, avoiding abrupt discontinuation.
• iNO may have a role in preterm neonates with hypoxemic respiratory failure, warranting further investigation.